(Q33770273)

29 July 2017

1 reference

title

Comparative tolerability of drug therapies for hypercalcaemia of malignancy (English)

1 reference

29 July 2017

N Zojer

1

1 reference

29 July 2017

A V Keck

series ordinal

2

1 reference

29 July 2017

M Pecherstorfer

series ordinal

3

1 reference

29 July 2017

publication date

1 November 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

21

1 reference

29 July 2017

issue

5

1 reference

29 July 2017

page(s)

389-406

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-199921050-00004

29 July 2017

exact match

0 references

cites work

Clodronate treatment in patients with malignancy-associated hypercalcemia

1 reference

12 December 2020

Treatment of tumor hypercalcemia with clodronate.

1 reference

12 December 2020

Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate

1 reference

12 December 2020

The diagnostic value of urinary pyridinium cross-links of collagen, serum total alkaline phosphatase, and urinary calcium excretion in neoplastic bone disease.

1 reference

12 December 2020

Bisphosphonate-induced bronchoconstriction in aspirin-sensitive asthma

1 reference

12 December 2020

Long-lasting dermatological lesions after tiludronate therapy

1 reference

12 December 2020

Parathyroid-hormone-related peptide in hematologic malignancies

1 reference

12 December 2020

Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein

1 reference

12 December 2020

Intravenous clodronate for the treatment of hypercalcaemia in breast cancer patients with bone metastases--a prospective randomised placebo-controlled multicentre study

1 reference

12 December 2020

One-shot high-dose pamidronate disodium (APD): effective, simple treatment for hypercalcaemia in haematological malignancy

1 reference

12 December 2020

Pharmacokinetics and therapeutic index of gallium nitrate

1 reference

12 December 2020

The use of nasal calcitonin spray in the treatment of hypercalcaemia of malignancy

1 reference

12 December 2020

Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia

1 reference

12 December 2020

Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia

1 reference

12 December 2020

Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer

1 reference

12 December 2020

[Treatment of hypercalcemia syndrome with mithramycin]

1 reference

12 December 2020

Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages

1 reference

12 December 2020

Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy

1 reference

12 December 2020

Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP

1 reference

12 December 2020

Direct evidence of a parathyroid related protein gradient between the mother and the newborn in humans

1 reference

12 December 2020

Acquired platelet dysfunction following mithramycin therapy

1 reference

12 December 2020

Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions.

1 reference

12 December 2020

Parathyroid hormone-related peptide (PTHrP) regulates fetal-placental calcium transport through a receptor distinct from the PTH/PTHrP receptor

1 reference

12 December 2020

A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate

1 reference

12 December 2020

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

1 reference

12 December 2020

Renal failure associated with intravenous diphosphonates

1 reference

12 December 2020

Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia

1 reference

12 December 2020

Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group

1 reference

12 December 2020

Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia

1 reference

12 December 2020

Iv dichloromethylene diphosphonate in cancer-associated hypercalcemia: a phase I-II evaluation

1 reference

12 December 2020

Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia

1 reference

12 December 2020

Adverse effects of bisphosphonates. A comparative review

1 reference

12 December 2020

Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia

1 reference

12 December 2020

Maintenance etidronate in the prevention of malignancy-associated hypercalcemia

1 reference

12 December 2020

A comparison of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD) in the treatment of hypercalcemia of malignancy

1 reference

12 December 2020

New approach to the treatment of hypercalcemia The effect of short-term treatment with mithramycin

1 reference

12 December 2020

Renal function and alterations in plasma electrolyte levels in normocalcaemic and hypercalaemic patients with malignant diseases, given an intravenous infusion of mithramycin

1 reference

12 December 2020

Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia

1 reference

12 December 2020

Gallium nitrate increases type I collagen and fibronectin mRNA and collagen protein levels in bone and fibroblast cells

1 reference

12 December 2020

Treatment of malignant hypercalcaemia with clodronate

1 reference

12 December 2020

Treatment of resistant tumor-induced hypercalcemia with escalating doses of pamidronate (APD)

1 reference

12 December 2020

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

1 reference

12 December 2020

Side-effects of pamidronate

1 reference

12 December 2020

Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, double-blind comparison to calcitonin

1 reference

12 December 2020

Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients

1 reference

12 December 2020

Mechanism of the Hypocalcemic Effect of Mithramycin*

1 reference

12 December 2020

Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.

1 reference

12 December 2020

A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates

1 reference

12 December 2020

Salmon Calcitonin in the Treatment of Hypercalcemia

1 reference

12 December 2020

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

1 reference

12 December 2020

Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate

1 reference

12 December 2020

Pamidronate disodium and possible ocular adverse drug reactions

1 reference

12 December 2020

Severe hypocalcaemia [corrected] after treatment with diphosphonate and aminoglycoside

1 reference

12 December 2020

Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium

1 reference

12 December 2020

Iritis following intravenous pamidronate

1 reference

12 December 2020

The physiology of parathyroid hormone-related protein: an emerging role as a developmental factor

1 reference

12 December 2020

Oral versus intravenous AHPrBP (APD) in the treatment of hypercalcemia of malignancy

1 reference

12 December 2020

Hepatic toxicity of low doses of mithramycin in hypercalcemia

1 reference

12 December 2020

Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy

1 reference

12 December 2020

Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia

1 reference

12 December 2020

Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center

1 reference

12 December 2020

Effectiveness of a 24-hour infusion of etidronate disodium in the treatment of hypercalcemia of malignant disease. A dose-ranging pilot study

1 reference

12 December 2020

Pamidronate in the treatment of tumor-associated hypercalcemia

1 reference

12 December 2020

Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand

1 reference

12 December 2020

Circulating PTHrP concentrations in tumor-induced hypercalcemia: influence on the response to bisphosphonate and changes after therapy.

1 reference

12 December 2020

Genes mediating glucocorticoid effects and mechanisms of their regulation.

1 reference

12 December 2020

Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations

1 reference

12 December 2020

A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy

1 reference

12 December 2020

A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia

1 reference

12 December 2020

Treatment of the hypercalcaemia of malignancy with intravenous clodronate.

1 reference

12 December 2020

Safety of pamidronate in patients with renal failure and hypercalcemia

1 reference

12 December 2020

Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection

1 reference

12 December 2020

Advances in bone biology: the osteoclast

1 reference

12 December 2020

Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia

1 reference

12 December 2020

Parathyroid hormone-related protein (PTHrP) does not regulate 1,25-dihydroxyvitamin D serum levels in hypercalcemia of malignancy

1 reference

12 December 2020

[Acute hepatic necrosis and hemorrhagic syndrome leading to a fatal outcome during treatment of hypercalcemia with mithramycin (author's transl)]

1 reference

12 December 2020

Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial

1 reference

12 December 2020

Measurement of N- and C-terminal-region fragments of parathyroid hormone-related peptide in milk from lactating women and investigation of the relationship of their concentrations to calcium in milk

1 reference

12 December 2020

Single dose versus daily intravenous aminohydroxypropylidene biphosphonate (APD) for the hypercalcaemia of malignancy

1 reference

12 December 2020

Distribution of trace levels of therapeutic gallium in bone as mapped by synchrotron x-ray microscopy

1 reference

12 December 2020

Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin

1 reference

12 December 2020

Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy

1 reference

12 December 2020

Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients

1 reference

12 December 2020

Comparison of intravenous (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate and volume repletion in tumour-induced hypercalcaemia

1 reference

12 December 2020

Etidronate disodium in the management of malignancy-related hypercalcemia

1 reference

12 December 2020

Nephrotoxicity following Single Dose Mithramycin Therapy

1 reference

12 December 2020

Monotherapy with clodronate for tumor-induced hypercalcemia

1 reference

12 December 2020

Treatment of malignant hypercalcaemia with aminohexane bisphosphonate (neridronate).

1 reference

12 December 2020

Gamma/delta T-cell stimulation by pamidronate

1 reference

12 December 2020

Long- and short-term side effects and safety of calcitonin in man: a prospective study

1 reference

12 December 2020

Hypercalcemia of malignancy

1 reference

12 December 2020

Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation

1 reference

12 December 2020

Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone

1 reference

12 December 2020

A comparison of low versus high dose pamidronate in cancer-associated hypercalcaemia

1 reference

12 December 2020

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

1 reference

12 December 2020

Disodium Pamidronate Versus Mithramycin in the Management of Tumour-Associated Hypercalcemia

1 reference

12 December 2020

Hypercalcemic crisis in neoplastic diseases: management with mithramycin

1 reference

12 December 2020

Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy

1 reference

12 December 2020

Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease

1 reference

12 December 2020

Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate

1 reference

12 December 2020

Gallium increases bone calcium and crystallite perfection of hydroxyapatite

1 reference

12 December 2020

3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer

1 reference

12 December 2020

Single high-dose (45 mg) infusions of aminohydroxypropylidene diphosphonate for severe malignant hypercalcemia

1 reference

12 December 2020

Toxic epidermal necrolysis after mithramycin.

1 reference

12 December 2020

Salmon calcitonin in hypercalcemia

1 reference

12 December 2020

10.2165/00002018-199921050-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1000195644

0 references

1 reference